Correlation between Serum Level of Matrix Metalloproteinase-2 with Left Ventricular End-diastolic Volume in Children with Heart Failure
DOI:
https://doi.org/10.3889/oamjms.2020.5107Keywords:
Children, Heart failure, Matrix metalloproteinase 2, Left ventricular end-diastolic volumeAbstract
BACKGROUND: Left ventricular end-diastolic volume (LVEDV) on echocardiography is one of the tests performed on heart failure. This refers to the volume of the left ventricle at the end of the diastolic phase, which would be increased when there is a disturbance in preload, afterload, and contractility factors. Matrix metalloproteinase-2 (MMP2) is a marker of congestive heart failure that can be examined through laboratory examinations.
AIM: The objective of the study was to provide evidence of the association between MMP and inflammatory process as well as its correlation with LVEDV in children with heart failure.
METHODS: This was a cross-sectional study conducted on children aged 3 months–12 years old with heart failure, who visited Sanglah Hospital, Denpasar, Indonesia from May 2017 to March 2018. Echocardiographic examination (LVEDV) and blood samples were taken to measure the serum level of MMP2 on day 1 after the subjects were diagnosed with heart failure.
RESULTS: A total of 32 subjects with heart failure were analyzed in this study. Acyanotic congenital heart defect (CHD) was the most common cause of heart failure, as observed in 23 subjects (71.9%). Characteristics data revealed that 24 subjects (75%) were underweight, 23 (71.9%) had cardiomegaly, and 22 (68.8%) had mild heart failure. Data analysis showed a moderate positive correlation between MMP2 levels with LVEDV after controlling for the influence of age (p = 0.02; r = 0.425).
CONCLUSION: There was a moderate positive correlation between MMP2 level and LVEDV after controlling for the age factor.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Mueller GC, Schlueter EL, Arndt F, Khatami JW, Mir TS. Prevalence of anemia in children with congestive heart failure due to dilated cardiomyopathy. Int J Pediatr. 2012;2012:452909. https://doi.org/10.1155/2012/452909 PMid:23213342
Beggs S, Thompson A, Nash R, Tompson A, Peterson G. Cardiac Failure in Children. 17th Expert Committee on the Selection and Use of Essential Medicines. Geneva: World Health Organization; 2009. p.1-31.
Hsu DT, Pearson GD. Heart failure in children: Part I: History, etiology, and pathophysiology. Circ Heart Fail. 2009;2:63-70. https://doi.org/10.1161/circheartfailure.108.820217 PMid:19808316
Frobel AK, Hulpke WM, Schmidt KG, Laer S. Beta blockers for congestive heart failure in children. Cochrane Database Syst Rev. 2009;1:CD007037. https://doi.org/10.1002/14651858.cd007037.pub2 PMid:19160314
Ross RD. The ross classification for heart failure in children after 25 years: A review and an age stratified revision. Pediatr Cardiol. 2012;33(8):1295-300. https://doi.org/10.1007/s00246-012-0306-8 PMid:22476605
Verma RP, Hansch C. Matrix metalloproteinases (MMPs): Chemical-biological functions and (Q)SARs. Bioorg Med Chem. 2007;15(6):2223-68. https://doi.org/10.1016/j.bmc.2007.01.011 PMid:17275314
Shirakabe A, Asai K, Hata N, Yokoyama S, Shinada T, Kobayashi N, et al. Clinical significance of matrix metalloproteinase (MMP)-2 in patients with acute heart failure. Int Heart J. 2010;51(6):404-10. https://doi.org/10.1536/ihj.51.404 PMid:21173516
Muller AL, Dhalla AS. Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev. 2012;17(3):395-409. https://doi.org/10.1007/s10741-011-9269-8 PMid:21739365
Tousoulis D, Kampoli AM, Papageorgiou N, Antoniades C, Siasos G, Latsios G, et al. Matrix metalloproteinases in heart failure. Curr Top Med Chem. 2012;12(10):1181-91. https://doi.org/10.2174/1568026611208011181 PMid:22519448
Banfi C, Cavalca V, Veglia F, Brioschi M, Barcella S, Mussoni L, et al. Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase 2 in human heart failure. Eur Heart J. 2005;26(5):481-8. https://doi.org/10.1093/eurheartj/ehi073 PMid:15618033
Sani UM, Ahmed H, Jiya NM. Pattern of acquired heart diseases among children seen in Sokoto, North-Western Nigeria. Niger J Clin Pract. 2015;18(6):718-25. https://doi.org/10.4103/1119-3077.163284 PMid:26289507
Abdulkadir M, Abdulkadir Z. A systematic review of trends and patterns of congenital heart disease in children in Nigeria from 1964-2015. Afr Health Sci. 2016;16(2):367-77. https://doi. org/10.4314/ahs.v16i2.5 PMid:27605952
Hassan BA, Albanna EA, Morsy SM, Siam AG, Shafie MM, Elsaadany HF, et al. Nutritional status in children with un-operated congenital heart disease: An Egyptian center experience. Front Pediatr. 2015;3:53. https://doi.org/10.3389/fped.2015.00053 PMid:26125014
Ratanachu S, Pongdara A. Nutritional status of pediatric patients with congenital heart disease: Pre and post cardiac surgery. J Med Assoc Thai. 2011;94(3):S133-7. PMid:22043766
Isezuo KO, Waziri UM, Sani UM, Garba BI, Ahmad MM, Adamu A, et al. Nutritional status of children with congenital heart diseases at a university teaching hospital, North-Western Nigeria. Int J Trop Dis Health. 2017;25(4):1-8. https://doi.org/10.9734/ijtdh/2017/35964
Cheng KS, Liao YC, Chen MY, Kuan TC, Hong YH, Ko L. Circulating matrix metalloproteinase 2 and 9 enzyme activities in the children with ventricular septal defect. Int J Biol Sci. 2013;9(6):557-63. https://doi.org/10.7150/ijbs.6398 PMid:23847438
Kihc Z, Ucar B, Ozdemir G, Colak O, Bal C, Ertugrul T. Circulating matrix metalloproteinase and tissue inhibitors of metalloproteinases levels in pediatric patients with congenital heart disease: Relationship to cardiac functions. Anatol J Cardiol. 2014;14(6):531-41. https://doi.org/10.5152/akd.2014.4950 PMid:25233500
Yamazaki T, Lee JD, Shimizu H, Uzui H, Ueda T. Circulating matrix metalloproteinase 2 is elevated in patients with congestive heart failure. Eur J Heart Fail. 2004;6:41-5. https://doi.org/10.1016/j.ejheart.2003.05.002 PMid:15012917
Baggen VJ, Eindhoven JA, Bosch AE, Witsenburg M, Cuypers JA, Langstraat JS, et al. Matrix metalloproteinase as candidate biomarkers in adults with congenital heart disease. Biomarkers. 2016;21(5):466-73. https://doi.org/10.3109/1354750x.2016.1153722 PMid:26983903
Panesar DK, Burch M. Assessment of diastolic function in congenital heart disease. Front Cardiovasc Med. 2017;4:5. https://doi.org/10.3389/fcvm.2017.00005 PMid:28261582
Figueroa MS, Peters JI. Congestive heart failure: Diagnosis, pathophysiology, therapy, and implications for respiratory care. Respir Care. 2006;51(4):403-12. PMid:16563194
Strait JB, Lakatta EG. Aging-associated cardiovascular changes and their relationship to heart failure. Heart Fail Clin. 2012;8(1):143-64. https://doi.org/10.1016/j.hfc.2011.08.011 PMid:22108734
Cain PA, Ahl R, Hedstrom E, Ugander M, Johnsson AA, Friberg P, et al. Age and gender specific normal values of left ventricular mass, volume and function for gradient echo magnetic resonance imaging: A cross sectional study. BMC Med Imaging. 2009;9:2. https://doi.org/10.1186/1471-2342-9-2 PMid:19159437
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Bagus Ngurah Mahakrishna, Eka Gunawijaya, I Wayan Dharma Artana, Ni Putu Veny Kartika Yantie, Made Kardana, I Putu Gede Karyana, Gusti Ayu Putu Nilawati (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
